Beta3-Integrin Reporter Constructs for Cancer Cell Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for drug screening and cancer research lack effective tools to identify agents that inhibit beta3-integrin (ITGB3) promoter-driven cancer cell survival, metastasis, and acquired resistance, as well as characterize distinct populations of cancer cells within the tumor microenvironment.
Innovation Solution
Development of nucleic acid constructs and recombinant cells with beta3-integrin (ITGB3) promoters operatively linked to reporters, such as luciferase or GFP, for screening compounds that inhibit cancer cell survival and metastasis, and for identifying novel pathways leading to acquired resistance and stemness, using engineered cell lines and non-human transgenic organisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional drug screening methods are used, then general cancer research can be conducted, but effective tools to identify agents that inhibit beta3-integrin promoter-driven cancer cell survival and metastasis cannot be obtained
Solution Approach 1:
The patent introduces a reporter gene (luciferase or GFP) as an intermediary element that is operatively linked to the beta3-integrin promoter. This reporter serves as a mediator that converts promoter activity into a detectable signal, enabling precise identification of compounds that inhibit beta3-integrin-driven cancer cell functions while maintaining the ability to screen through multiple cancer types and contexts.
2Measurement precision
If beta3-integrin promoter linked to reporter is used, then identification of anti-cancer agents is enabled, but device complexity increases due to engineered cell lines and transgenic organisms
Solution Approach 1:
The patent segments the screening system into modular components: the beta3-integrin promoter region is isolated and linked to a reporter gene in a nucleic acid construct, which can then be introduced into various cell lines or organisms. This segmentation allows the complex screening capability to be distributed across multiple simple, standardized components rather than requiring entirely engineered systems.
3Productivity
If reporter genes are used to monitor promoter activity, then compound screening becomes possible, but loss of time occurs in developing and validating engineered cell lines
Solution Approach 1:
The patent performs preliminary action by pre-construction and validation of the nucleic acid construct containing the beta3-integrin promoter linked to the reporter gene. This construct can be stored and repeatedly introduced into different cell lines or organisms, eliminating the need to re-engineer the promoter-reporter linkage for each screening experiment and significantly reducing development time.
4Loss of information
If conventional screening methods are used, then general drug testing can be performed, but characterization of distinct cancer cell populations in tumor microenvironment cannot be achieved
Solution Approach 1:
The patent applies local quality by using the reporter gene expression to specifically highlight and differentiate local variations in beta3-integrin promoter activity among distinct cancer cell populations within the tumor microenvironment. This allows heterogeneity to be visualized and characterized without requiring complex multi-parameter analysis systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the identification of compounds that inhibit cancer cell survival, metastasis, and reverse acquired resistance, while characterizing distinct cancer cell populations, thereby facilitating the development of targeted cancer therapies.
Implementation Method 1
the reporter or marker protein or compound is a bioluminescent or a fluorescent protein or compound, or a luciferase
Implementation Method 2
the reporter or marker protein or compound is a bioluminescent or a fluorescent protein or compound, or a green fluorescent protein (GFP)
Data Source
AI summary
In alternative embodiments, provided are products of manufacture, such as assays, chimeric nucleic acids and nucleic acid constructs, recombinant cells, and methods, comprising use of beta3-integrin (ITGB3) promoters operatively linked to a reporter, for drug screening, and in particular, screening for agents that inhibit cancer cell survival and metastasis. In alternative embodiments, compositions and methods as provided herein also can be used to identifying novel pathways that lead to acquired resistance, stemness, and anchorage independent growth; and characterizing distinct populations of cancer cells within a tumor microenvironment.